Back to Search
STEVEN O'DAY, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1518070812Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
A53519(CA)
Research & Publications (20)
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
PMID 18000991·Cancer·2007
6-review
Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis.
PMID 12777988·Melanoma Res·2003
3-trial
Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
PMID 12231516·Clin Cancer Res·2002
3-trial
High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.
PMID 11505406·Cancer·2001
3-trial
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma.
PMID 19643020·BMC Cancer·2009
3-trial
Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
PMID 19536884·Cancer·2009
3-trial
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
PMID 19349552·J Clin Oncol·2009
3-trial
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
PMID 19671877·Clin Cancer Res·2009
3-trial
mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads.
PMID 19233913·Clin Chem·2009
8-other
Phase I/II study of ipilimumab for patients with metastatic melanoma.
PMID 19018089·J Clin Oncol·2008
3-trial
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
PMID 17404088·Clin Cancer Res·2007
8-other
Estrogen receptor-alpha methylation predicts melanoma progression.
PMID 16818643·Cancer Res·2006
8-other
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
PMID 16809738·J Clin Oncol·2006
3-trial
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma.
PMID 16379038·Invest New Drugs·2006
3-trial
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.
PMID 16489066·Clin Cancer Res·2006
8-other
Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.
PMID 16778184·Cancer Res·2006
8-other
Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma.
PMID 16946711·J Invest Dermatol·2006
8-other
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
PMID 16361635·J Clin Oncol·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2121 SANTA MONICA BLVD
SANTA MONICA, CA 90404 - Phone
- (310) 829-8317
Quick Facts
- NPI
- 1518070812
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile